Becton, Dickinson and Company (BDX) said Tuesday it will invest $110 million to establish BD Neopak glass prefillable syringe production at its site in Columbus, Nebraska, with supply expected to begin in mid-2026.

BD Neopak glass prefillable syringe production will be available in 1 mL and 2.25 mL formats, the company said.

A part of the investment will go toward additional line upgrades and capacity improvements at the facility.

BD will also invest $10 million to improve cannula manufacturing capabilities at the site.

BD said these investments are expected to create around 120 new jobs.